These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 12534781

  • 21. [Impact of antiviral therapy on the natural history of hepatitis C virus].
    Fernández Rodriguez CM, Gutierrez Garcia ML.
    Gastroenterol Hepatol; 2014 Dec; 37(10):583-92. PubMed ID: 25066318
    [Abstract] [Full Text] [Related]

  • 22. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y, Tateishi R, Yoshida H, Omata M.
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract] [Full Text] [Related]

  • 23. [Etiology of hepatocellular carcinoma. The problem of the primary disease].
    Sterneck M.
    Internist (Berl); 2000 Feb; 41(2 Pt 2):185-90. PubMed ID: 10756433
    [No Abstract] [Full Text] [Related]

  • 24. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
    Gonzalez HC, Gordon SC.
    Gastroenterol Clin North Am; 2020 Jun; 49(2):301-314. PubMed ID: 32389364
    [Abstract] [Full Text] [Related]

  • 25. [Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschr Med; 2009 May 28; 151(22):38-9. PubMed ID: 19526965
    [No Abstract] [Full Text] [Related]

  • 26. Impact of hepatitis B therapy on the long-term outcome of liver disease.
    Liaw YF.
    Liver Int; 2011 Jan 28; 31 Suppl 1():117-21. PubMed ID: 21205148
    [Abstract] [Full Text] [Related]

  • 27. Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity.
    Piconese S, Cammarata I, Barnaba V.
    J Autoimmun; 2018 Dec 28; 95():58-68. PubMed ID: 30509387
    [Abstract] [Full Text] [Related]

  • 28. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E, Bergk A, Berg T.
    Z Gastroenterol; 2008 Jan 28; 46(1):69-80. PubMed ID: 18188819
    [Abstract] [Full Text] [Related]

  • 29. Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?
    Lim LY, Kowdley KV.
    Gastroenterology; 2005 Dec 28; 129(6):2120-2; discussion 2122. PubMed ID: 16344085
    [No Abstract] [Full Text] [Related]

  • 30. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    Kim BS, Seo YS, Kim YS, Lee CH, Lee HA, Um SH, Yoo JJ, Kim SG, Suh SJ, Jung YK, Ahn SH, Han KH, Yim HJ, Kim SU, Korean Transient Elastography Study Group.
    J Gastroenterol Hepatol; 2018 Feb 28; 33(2):503-510. PubMed ID: 28666070
    [Abstract] [Full Text] [Related]

  • 31. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M, Della Corte C, Colombo M.
    Liver Int; 2014 Feb 28; 34 Suppl 1():139-45. PubMed ID: 24373091
    [Abstract] [Full Text] [Related]

  • 32. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A, Venkataraman J.
    Singapore Med J; 2012 Apr 28; 53(4):231-5. PubMed ID: 22511042
    [Abstract] [Full Text] [Related]

  • 33. [Chronic hepatitis C: from discovery to cure].
    Li Q, Huang YX, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep 20; 24(9):708-712. PubMed ID: 27788732
    [Abstract] [Full Text] [Related]

  • 34. [Influence of treatment on long-term evolution of chronic hepatitis B].
    Zarski JP.
    Gastroenterol Clin Biol; 2010 Sep 20; 34 Suppl 2():S109-11. PubMed ID: 21095513
    [Abstract] [Full Text] [Related]

  • 35. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul 20; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 36. Hepatitis B virus vaccine for patients with hepatitis C virus infection.
    Chlabicz S, Grzeszczuk A.
    Infection; 2000 Jul 20; 28(6):341-5. PubMed ID: 11139151
    [Abstract] [Full Text] [Related]

  • 37. When (and When Not) to Treat Patients With HBV Infection.
    Fricker ZP, Reddy KR.
    Clin Gastroenterol Hepatol; 2019 Dec 20; 17(13):2644-2647. PubMed ID: 31154025
    [No Abstract] [Full Text] [Related]

  • 38. Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
    Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka S, Toshimori J, Kobashi H, Kariyama K, Morimoto Y, Takayama H, Seno T, Takaguchi K, Moriya A, Miyatake H, Okamoto R, Yabushita K, Takaki A, Yamamoto K.
    Acta Med Okayama; 2016 Dec 20; 70(1):1-12. PubMed ID: 26899604
    [Abstract] [Full Text] [Related]

  • 39. [The prophylaxis of hepatocellular carcinoma by interferon-alpha in virus-induced cirrhosis].
    Merle P, Zoulim F, Vitvitski L, Trépo C.
    Gastroenterol Clin Biol; 2000 Dec 20; 24(12):1166-76. PubMed ID: 11173729
    [No Abstract] [Full Text] [Related]

  • 40. End points of therapy in chronic hepatitis B.
    Ahmed SN, Ecochard M, Zoulim F.
    Expert Rev Gastroenterol Hepatol; 2010 Feb 20; 4(1):37-49. PubMed ID: 20136588
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.